Sartorius_May21_NeutAntiMakingTheir - 24

NEUTRALIZING ANTIBODIES MAKING THEIR MARK IN NEXT WAVE OF BIOLOGICS

SARS-CoV-2 Variants B.1.351
and B.1.1.7 Show Resistance to
Neutralizing Antibodies

E

ach passing week brings

paper, " Antibody Resistance of SARS-CoV-2

more questions about the

Variants B.1.351 and B.1.1.7. " A preprint of

SARS-CoV-2 variants. One of the

the study was first posted to BioRxiv on

biggest questions has been whether
the emerging variants will respond

January 26, 2021.
Monoclonal antibodies, which target

differently to neutralizing antibodies

specific sites on the SARS-CoV-2 virus, are

made by people who have been infected.

being used in hospitals to treat COVID-19.

This point is important to understand,

However, these therapeutics were designed

as it may alter the ability of our current

to work against the initial variant of

arsenal of therapeutics and vaccines to

SARS-CoV-2, which emerged in 2019.

combat the infection.
Now, new research from the labs at the

David Ho, MD, professor of microbiology
& immunology and director, Aaron Diamond

Aaron Diamond AIDS Research Center at the

AIDS Research Center, and colleagues,

Columbia University College of Physicians

assessed the ability of 30 monoclonal

and Surgeons, suggests that two of the

antibodies, along with plasma from 20

variants, the B.1.351 and B.1.1.7 SARS-CoV-2

patients who recovered from COVID-19

variants (first detected in South Africa and

and sera from 22 people who have been

the U.K., respectively), show increased

vaccinated, to neutralize the B.1.351 and

resistance to antibody neutralization in

B.1.1.7 variants of SARS-CoV-2.

laboratory experiments. The findings
suggest that current antibody therapies and

ADDITIONAL CONTENT

vaccines may be less effective against some

Infographic:

variants of the virus.
This work is published in Nature, in the

DEVELO
PIN
MONOCL G
O
ANTIBOD NAL
IES:
CHALLE
NGES
TIONS

+ SOLU

Developing Monoclonal Antibodies:
Challenges + Solutions
CHALL

Monoclo
nal anti
bodies (mA
immune
bs) used
system
to mount
for imm
therapeu
unother
a response
tics are
apy stim
being used
to target
autoimm
ulate the
antigens
une dise
to target
. These
ases, and
various
function
powerfu
condition
those with
are the
l
s including
best cand
superior
method
idates for
ological
target reac
cancer
and
advancem
developm
tivity and
challeng
ents, deve
ent. Desp
ing. Here
optimal
loping new
ite tech
we expl
nologica
ore som
monoclo
l and
e common
nal anti
bodies can
challeng
es and pote
be
ntial solu
tions.

ENGE

How do
I determ
ine and
validate
target sele
ction?

24 |

GENengnews.com

SOLUT

ION

Compre
hensive,
biologica
relevant
lly
assays.

Monoclo
nal antib
ody deve
antigen.
lopment
Choosing
requires
a system
compreh
that enab
ensive eval
les kinetic,
uation of
multiplex
both the
ed results
mAb and
ensures
target
predictiv
e target
selection

TH E
IN CU CY
TE
LIV E- CE ®
LL
AN AL YS
IS
SY ST EM

enables
real-time
,
live-cell
imaging
and a

.


https://www.sartorius.com/en/pr/mab/challenges-and-solutions-for-developing-new-monoclonal-antibodies http://www.GENengnews.com

Sartorius_May21_NeutAntiMakingTheir

Table of Contents for the Digital Edition of Sartorius_May21_NeutAntiMakingTheir

Contents
Sartorius_May21_NeutAntiMakingTheir - 1
Sartorius_May21_NeutAntiMakingTheir - 2
Sartorius_May21_NeutAntiMakingTheir - 3
Sartorius_May21_NeutAntiMakingTheir - Contents
Sartorius_May21_NeutAntiMakingTheir - 5
Sartorius_May21_NeutAntiMakingTheir - 6
Sartorius_May21_NeutAntiMakingTheir - 7
Sartorius_May21_NeutAntiMakingTheir - 8
Sartorius_May21_NeutAntiMakingTheir - 9
Sartorius_May21_NeutAntiMakingTheir - 10
Sartorius_May21_NeutAntiMakingTheir - 11
Sartorius_May21_NeutAntiMakingTheir - 12
Sartorius_May21_NeutAntiMakingTheir - 13
Sartorius_May21_NeutAntiMakingTheir - 14
Sartorius_May21_NeutAntiMakingTheir - 15
Sartorius_May21_NeutAntiMakingTheir - 16
Sartorius_May21_NeutAntiMakingTheir - 17
Sartorius_May21_NeutAntiMakingTheir - 18
Sartorius_May21_NeutAntiMakingTheir - 19
Sartorius_May21_NeutAntiMakingTheir - 20
Sartorius_May21_NeutAntiMakingTheir - 21
Sartorius_May21_NeutAntiMakingTheir - 22
Sartorius_May21_NeutAntiMakingTheir - 23
Sartorius_May21_NeutAntiMakingTheir - 24
Sartorius_May21_NeutAntiMakingTheir - 25
Sartorius_May21_NeutAntiMakingTheir - 26
Sartorius_May21_NeutAntiMakingTheir - 27
Sartorius_May21_NeutAntiMakingTheir - 28
Sartorius_May21_NeutAntiMakingTheir - 29
Sartorius_May21_NeutAntiMakingTheir - 30
Sartorius_May21_NeutAntiMakingTheir - 31
Sartorius_May21_NeutAntiMakingTheir - 32
Sartorius_May21_NeutAntiMakingTheir - 33
Sartorius_May21_NeutAntiMakingTheir - 34
Sartorius_May21_NeutAntiMakingTheir - 35
Sartorius_May21_NeutAntiMakingTheir - 36
Sartorius_May21_NeutAntiMakingTheir - 37
Sartorius_May21_NeutAntiMakingTheir - 38
Sartorius_May21_NeutAntiMakingTheir - 39
Sartorius_May21_NeutAntiMakingTheir - 40
Sartorius_May21_NeutAntiMakingTheir - 41
Sartorius_May21_NeutAntiMakingTheir - 42
https://www.nxtbookmedia.com